



# Bioscene

**Bioscene**

**Volume- 21 Number- 04**

**ISSN: 1539-2422 (P) 2055-1583 (O)**

**[www.explorebioscene.com](http://www.explorebioscene.com)**

## HPV Vaccination: A Review Article

**Satyapriya Roy<sup>1,\*</sup>, Chayanika Sharma<sup>2</sup>, Ahalya. A<sup>2</sup>, Apoorva Dev M<sup>3</sup>,  
Shilpi Saha<sup>4</sup>**

<sup>1</sup>Assistant Professor, Department of Human Physiology, Government Degree College, Kamalpur, Dhalai Tripura, India

ORCID ID: 0000-0002-5277-2526

<sup>2</sup>Intern Student, 6<sup>th</sup> semester, Pharmacy practice, Pharm.D, East West College of Pharmacy, Rajiv Gandhi University of Health Science, India

ORCID ID:0009-0007-5614-319X

<sup>3</sup>Associate Professor, East West College of Pharmacy, Rajiv Gandhi University of Health Science, Bengaluru, Karnataka, India.

<sup>4</sup>Assistant Professor, Department of MLT, Bhavan's Tripura College of Science and Technology (BTCST), Anandanagar, West Tripura, India

ORCID ID: 0000-0002-5629-9035

\*Corresponding Author: **Satyapriya Roy**

---

---

**Abstract:** Cervical cancer is a leading cause of cancer-related deaths among women worldwide, primarily caused by mortal papillomavirus (HPV) infection, especially high-risk strains HPV 16 and HPV 18. It is generally transmitted sexually, with both vertical and perpendicular transmission modes. Beforehand discovery through webbing and forestalling via HPV vaccination significantly reduces the complaint burden. The HPV vaccine, offering long-lasting impunity, is most effective when administered at a young age before exposure to the contagion. Despite its proven efficacy, public awareness of the vaccine remains limited. Mindfulness juggernauts in seminaries, universities, and through social media can help educate people about the significance of vaccination. General interpreters also play a pivotal part in propagating vaccine-related information. Exploration indicates that HPV vaccination has led to a decline in cervical pre-cancer cases among young women. Vaccines, which stimulate cell-mediated impunity, are preventative and can not treat cervical cancer, emphasizing the need for early administration. Ongoing exploration aims to enhance understanding of HPV, ameliorate vaccination strategies, and increase public knowledge, which can further drop the global cancer burden. Among all cancers, cervical cancer is unique in having an effective vaccine for forestalled. This review highlights the significance of HPV vaccines, their safety, and the necessity of public mindfulness to reduce cervical cancer prevalence and associated mortality encyclopedically.

**Keywords:** Cancer, Cervical cancer, Vaccine, Efficiency, Detection, Awareness, Safety

---

---

**Introduction of HPV:**

Human papillomavirus (HPV) includes a wide variety of viruses, with around 200 different stereotypes that can infect humans. HPV is a prevalent sexually transmitted infection. Almost all sexually active people will be infected at some point in their lives, usually without symptoms. HPV can affect the skin, genital area and throat. While condoms can help reduce the risk of HPV transmission, they do not provide complete protection as they leave some genital skin uncovered. Most HPV infections resolve independently, without needing treatment. Certain strains of HPV can lead to the development of genital warts, while others may result in unusual cell growth that can progress to cancer. Some HPV infections can result in small, rough growths known as genital warts, which may develop on the vagina, penis, or anus, and occasionally in the throat. These warts can be painful, itchy, might bleed, or cause swollen lymph nodes. Persistent HPV infection can cause abnormalities to in cervical cells, if it's not treated properly future it can progress to cervical cancer. It typically takes around 15 to 20 years for cervical cancer to manifest after an HPV infection. Early alterations in cervical cells and precancerous conditions usually do not produce any noticeable symptoms. Symptoms associated with cervical cancer can include bleeding between menstrual periods or after sexual intercourse, as well as a vaginal discharge with an unpleasant odor. These symptoms may also be attributed to other health issues. Individuals experiencing these symptoms should consult their healthcare provider.<sup>1</sup>

**Vaccine coverage:**

Denmark's comprehensive HPV vaccination initiative demonstrated that the chance of experiencing cervical dysplasia (cervical intraepithelial neoplasm grades 2/3 and 3) decreased by as much as 80% in those vaccinated compared to those who were not vaccinated, according to a cohort study. A randomized, double-blind trial included over 14000 women between the ages of 16 and 26 from around the globe who received three doses of either the 9-valent or the quadrivalent HPV vaccine. Urogenital tissue samples were collected at regular intervals for a duration of up to 54 months and tested for HPV infection. This vaccination could provide protection against around 90% of cervical malignancies, an increase 70% above the coverage offered by the quadeivalent HPV vaccine. The 9-valent HPV vaccine shares a similar structure with the quadrivalent vaccine, utilizing virus-like particles to stimulate an immune response.<sup>2</sup> The HPV vaccination is demonstrating positive results; The newly developed 9-valent HPV vaccine aims to enhance protection against an additional five strains (specifically, HPV types 31, 33, 45, 52, and 58), totaling 9 strains. This vaccine could provide protection against roughly 90% of cervical cancers, an increase from the 70% coverage offered by the quadrivalent HPV vaccine (level II). The 9-valent HPV vaccine shares a similar composition with the quadrivalent

vaccine, employing virus-like particles to stimulate immune responses.<sup>2</sup>As of 31 March 2017, in 71 countries, government immunization programmes are available for females, whereas 11 countries also offer for boys. Three quadrivalent vaccine received its license in 2006, the bivalent vaccine in 2007, and the covalent vaccine in 2014. All of these vaccines are recommended to be given ideally before individuals become sexually active.<sup>3</sup> Evidence shows broader spectrum protection against the types associated with nearly 90% of cervical cancers, achieved either through direct protection against a higher number of types (the second-generation 9-valent vaccine) or through cross-protection against non-vaccine types (the bivalent vaccine). Still, because vaccines are primarily targeted at pre-adolescent or juvenile adolescents, it is anticipated to take several decades after deployment in a population before their full benefits in terms of cancer prevention are realized, and a substantial impact of vaccines on cervical cancer frequency or mortality issues is yet to be observed. To date, vaccine content in Mics has been low overall, with an estimated 3 of the primary targeted population of juvenile girls in less developed regions vaccinated by 2014. Vaccination was assumed to range up to 90 content from 2020 with 100 continuance broad spectrum protection against HPV oncogenic types 16, 18, 31, 33, 45, 52, and 58 in individualizes susceptible to the applicable type; The analysis thus applies to a broad-spectrum vaccine that protects against these types either by direct protection (as per an alternate-generation 9-valent vaccine) or via cross protection on non-vaccine-included types.<sup>4</sup>

### **Epidemiology of HPV:**

The mortal papillomavirus (HPV) vaccine, which was approved by the US Food and Drug Administration in 2006, has demonstrated capability to help prevent cancer and cancer related to HPV. In the United States, about 34,800 cancers per time are attributable to HPV, the majority of which is cervical and pharyngeal cancers, but they also include anal, vaginal, vulvar, and penile cancers. Pharyngeal cancers associated with HPV, which aren't detected with routine webbing, now outnumber cervical cancers and are on the rise in the United States. In high-uptake countries, research has demonstrated that the two carcinogenic HPV types targeted by early HPV vaccines (HPV 16 and HPV 18) has been completely eradicated. Yet current estimates show that only 54 of American adolescents have completed the HPV vaccination series (note that HPV vaccination is administered as a two-cure series for utmost persons who initiate vaccination at periods 9 through 14 times, or as a three-cure series for persons who initiate vaccination at periods 15 through 45 times, and for vulnerable compromised persons. Although this represents an enhancement over the once decade, vaccine content still lags markedly behind public health pretensions and behind other vaccines recommended by the Advisory Committee on Immunization Practices.<sup>5</sup> According to World Health Organization's (WHO)

statistics, common cancers are one of the most current causes of mortality worldwide with 8.2 million deaths in 2012, and this trend has not changed in recent times. Viral infections contribute to 15–20 of all mortal cancers, whereby several contagions play significant places in the multistage development of nasty cancers. The correlation between a given contagion and its associated cancer ranges from 15 to 100. Cancer came a precedence public health challenge in Kazakhstan as a Member State of the WHO. Cervical cancer is the alternate most common cancer among women each over the world, with further than 85 of the cases being in developing countries. Maximum cervical cancer cases are caused by HPV infection. HPVs are a large group of contagions, which consists of further than 180 different types, among which 15 have high oncogenic parcels. HPV infection can lead to colorful cancer is one of the most current causes of mortality worldwide. In the cervix it is considered to be caused by different high-threat mortal papilloma contagion(HPV) types. Although numerous studies have formerly been conducted worldwide on the epidemiology of HPV infection and their oncogenic parcels, limited data are available on HPV frequency, prevalence, and genotype specific dispersion in Kazakhstan. <sup>6</sup>

#### **HPV Vaccine Type:**

Research was conducted to combat the substantial complaint burden, and sweats have led to the development of largely effective vaccines i) Bivalent HPV vaccine(HPV), ii) Quadrivalent HPV vaccine(HPV), iii) Nine- talent HPV vaccine(9vHPV).<sup>7</sup>

HPV type 16 is the most dangerous, accounting for the majority of cancer cases. HPV types 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 cause cervical cancer. The L1 protein, which, when assembled into contagion-suchlike patches, induces HPV-type-specific neutralizing antibodies, forms the base of all marketable HPV vaccines. There are six certified precautionary HPV vaccines three bivalent, two quadrivalent and one covalent vaccine. The bivalent vaccines cover from HPV types 16 and 18, which are associated with cervical cancers. Precautionary vaccination targets children before sexual debut, but there are now catching- up juggernauts, which have also been shown to be salutary in reducing HPV infection and complaint. HPV vaccination of grown-ups after treatment for cervical lesions or intermittent respiratory papillomatosis has impacted rush. Gender-neutral vaccination will ameliorate herd impunity and help infection in men and women. HPV vaccines are immunogenic in HPV patients, but further research is needed to assess the long - term impact and if additional boosters are necessary.<sup>8</sup>

The three presently available vaccines are(i) Cervarix(GlaxoSmithKline), a two-talent(2- V) vaccine targeting HPV16and 18, the most carcinogenic types(ii) Gardasil(Merck Inc.) A four talent(4- V) vaccine targeting HPV16/ 18 and also low-threat types HPV6 and 11 that beget genital knobs and(iii) Gardasil 9(Merck Inc.), a

nine-valent(9- V) vaccine targeting HPV6/ 11/16/18 and the coming five most carcinogenic types(HPV31/ 33/45/52/ 58). In addition to cervical cancer, substantial proportion of cancers of the vulva, vagina, penis, anus, and oropharynx are due to HPV.<sup>9</sup>

#### **Mechanism of Action of HPV vaccine:**

Presently, the certified HPV vaccines are developed based on a contagion- such as flyspeck(VLP) of the major papillomavirus capsid protein L1. Since VLPs are simply protein and don't contain viral genome, these are considered non-infectious and non-oncogenic, and therefore are safer than HPV- downgraded vaccines. VLPs can be produced in bacteria, yeast, or nonentity cells. Cervarix uses HPV16 and 18 VLPs, monophosphoryl lipid, and aluminum hydroxide as an adjuvant. MPL is a toll-like receptor 4(TLR4) agonist that can induce high titers of antibodies as compared to Gardasil and Gardasil 9, both of which contain only aluminum hydroxide as an adjuvant and are produced in *Saccharomyces cerevisiae* yeast. Gardasil has VLPs against HPV6, 11, 16, and 18, while Gardasil 9 has VLPs against HPV6, 11, 16, 18, 31, 33, 45, 52, and 58. The HPV vaccines presently being produced are grounded on L1- VLPs, which only give type restricted immunity, neglecting numerous other oncogenic HPV genotypes. Accordingly, the second generation VLPs, similar as L2- VLP and bivalent L1- L2 VLP, are drawing a lot of attention for their broader genotype content. In comparison to L1- VLP, the minor capsid protein, L2, contains type-common epitopes that can give broad cross-neutralizing antibody responses. Specially, Cervarix can confer a degree of cross-protection against some phylogenetically related types of HPV16 and 18 from the same phylogenetic cluster and 9 and 7 species groups, owing to its unique adjuvant systems.<sup>10</sup>

#### **Effectiveness of HPV Vaccination:**

HPV vaccination offers an occasion to greatly reduce the morbidity and mortality of HPV-associated complaint, but the short- and long-term impact of vaccination on equity is unclear. Multitudinous simulation models have been developed, across a variety of countries and settings, to estimate the impact or cost-effectiveness of HPV vaccination, inform policy, and assess the long-term impact of interventions to ameliorate HPV vaccination. The unequivocal addition of totally marginalized populations in decision models may help demonstrate the impact of vaccination on health injuries as well as companion crucial policy opinions and perpetration of interventions targeting HPV vaccine uptake to maximize effectiveness, effectiveness, and equity.<sup>4</sup>

Presently, cervical cancer is the only HPV- caused cancer for which screening tests are available. Screening tests are used to check for complaints when there are no symptoms. The thing of screening for cervical cancer is to find precancerous cell

changes before they come to cancer and when treatment can help cancer from developing. Cervical cancer screening is a part of standard healthcare for those with a cervix. This includes women and some bisexual men who still have a cervix. Cervical cancer is the most common type of cancer caused by HPV, and other less common cancers affecting men and women, including anal, vulvar, vaginal, mouth/throat, and penile cancers. Cancers from HPV can be averted with vaccines. The vaccine doesn't contain any live contagion or DNA from the contagion, so it can not cause cancer or other HPV-related ails. The HPV vaccine isn't used to treat HPV infections it's given as a booster dose. Utmost people don't have any symptoms from an HPV infection. The vulnerable system generally clears HPV from the body within a time or two with no lasting goods. An electronic hunt of the databases was carried out to recoup information concerning HPV vaccine perpetration between July 2006 and 2017, with special emphasis on the current shoes, difficulties, and ethical issues. Encyclopaedia, 74 countries have enforced the HPV vaccine in the public immunization schedule, and this vaccine is listed as an essential drug by WHO. About 60 of the low - and lower - middle - income countries have enforced the vaccine with fiscal backing Gave and WHO. Still, long-term follow-up is essential to substantiate the impact of the vaccination programs in cancer forestalled.<sup>11</sup>The US Food and Drug Administration(FDA) has approved three HPV- vaccines quadrivalent- Gardasil ®, Cervix ®, and Gardasil ® 9, conforming of type-specific HPV L1 contagion-suchlike patches(VLPs) that induce type-confined protection. All three vaccines help HPV16 and HPV18 infections, which are responsible for about 70 cases of cervical cancer and precancerous cervical lesions. Quadrivalent- Gardasil ® also protects against HPV6 and HPV11, which beget 90 of genital knobs. Gardasil ® 9 targets a fresh five cancer-causing HPV types 31, 33, 45, 52, and 58. Since the first licensure of HPV- vaccination in 2006, numerous countries have enforced intimately funded HPV- vaccination programs, with a variety of experimental studies establishing vaccine efficacy and impact. HPV- vaccination has been proven to be safe, immunogenic, and associated with dropped HPV infection rates and lowered threat of HPV related conditions. From 2007 to 2014, a seven years follow-up of the three -cure HPV vaccine series in nine high -income counntries resulted in a 68% decrease in the prevalence of HPV 16 and 18.

In 2012, the quadrivalent- Gardasil ® vaccine was introduced into the academy-grounded vaccination program for 10–12 years old girls. Meanwhile, a catch-up vaccination included youthful women up to 26 times of age in Stockholm, Sweden, which increased the total vaccine content. HPV is the most common sexually transmitted infection, with nearly half of Americans infected. HPV is generally acquired shortly after sexual debut, with a peak prevalence between the periods of 15 and 25 times. An estimated 80 of the HPV infections that go on to beget cancer are acquired before age 26. Although utmost infections regress spontaneously within 1

to 2 times, the longer the infection persists in a sensible state, the more advanced the threat of cervical pre-cancer or cancer. Cervical cancer precursors, or pre-cancer, are described histopathologically as a lesion (HAIL), or cervical intraepithelial neoplasm grades 2 and 3(CIN2 or CIN3). In general, pre-cancers are diagnosed approximately 5 to 10 times following the original oncogenic infection, with peak frequency between periods 25 and 35. Still, roughly 0 of high-grade pre-cancers ultimately come as invasive cancers if left undressed. Cervical cancer rates begin to rise in the mid-30s, peaking at periods 35 to 45 times, and remain high into aged periods.<sup>9</sup>

### **Detection of HPV infection:**

By the webbing test, we can detect HPV. Cervical cytology, HPV primary webbing, and cytology all reduce cervical cancer prevalence and mortality if guidelines are followed.<sup>12</sup>

#### Cervical cytology (Pap testing):

Pap smears are a lifesaving webbing tool for cervical cancer. The test can detect abnormal cells in your cervix before they become cancerous. Healthcare providers frequently perform HPV tests during Pap tests to check for HPV, one of the leading causes of cervical cancer. An unclear or unusual Pap smear result may be a sign of infection, another problem, or cancer.

A Pap involves using a small encounter to gently take a sample from the cervix to check for precancerous cells. A Pap smear is a procedure in which your healthcare professional collects a sample of cells from your cervix to investigate cell abnormalities that may lead to cervical cancer. A Pap smear prevents cervical cancer. The test checks for unusual cells on your cervix that are cancerous or have the eventuality to come cancerous and may also detect certain infections and inflammation. The test is named for an American croaker, papanicolaou, whonicolaou, who developed the Pap smear.

Pap smears should be performed at least every three months for women aged at 21-30. Between the periods of 30 and 65, you should have one every five times. A Pap smear is considered the gold standard for avoiding cervical cancer since it reveals cervical cell alterations before they might involve into cancer.<sup>13</sup>

#### Human Papillomavirus Primary Screening:

For HPV test collection of a cervical or vaginal sample to describe of the presence of an oncogenic HPV infection. Still, the capability to descry an oncogenic HPV infection is analogous when using a tone-collected vaginal tar or a clinician-collected sample, making tone-slice a possible option for the future. A meta-analysis of 56 studies set up that HPV assays using polymerase chain response technology were as sensitive with tone-samples as with clinician-collected samples, although assays grounded on signal modification were less sensitive.<sup>14</sup> mRNA assays also



seems to be less sensitive when attained via tone-collection compared with clinician collection.<sup>15</sup> Trials are presently underway to define the parameters for broader use of tone-collected samples. One advantage to tone-slice is the implicit to increase webbing participation in populations that presently witness high cancer rates because of lack of webbing, specifically those living in low-resource settings.<sup>16</sup>

HPV testing, whether clinician-collected or tone-collected, is more sensitive than cytology. A single HPV test detects 90 of pre-cancers and cancers.<sup>17</sup> therefore, the negative prophetic value( consolation) of HPV testing is far better than cytology and allows safe extension .<sup>18,19</sup> Testing employing HPV assays at 5 time intervals results in a decreased the treat of cancer and pre-cancer compared to cytology testing at three time intervals.<sup>19</sup> HPV succession negative tests give expansive protection, yielding a threat for high-grade pre-cancel of smaller than 1 case per 1000 cases screened.<sup>20,21</sup>

Another advantage of HPV testing is superior discovery of adenocarcinoma and its precursors compared with cytology.<sup>22</sup> Cytology samples frequently appear normal indeed when adenocarcinoma and adenocarcinoma in situ(AIS) are present, with the consequence that cytology-grounded webbing programs that effectively reduce rates of scaled cancers don't reduce rates of adenocarcinomas and AIS.<sup>17,23,24</sup> Because HPV testing leads to earlier discovery of scaled and glandular pre-cancers(CIN3/AIS), incorporating HPV testing into cervical cancer webbing programs reduces cancer prevalence within 5 times and mortality within 8 times compared with cytology webbing alone.<sup>25</sup>

Although randomized trials of Pap and HPV testing constantly demonstrate that HPV testing identifies pre-cancers before, the proportion of abnormal results is advanced when screening with HPV tests compared with cytology alone 10 and 6, independently.<sup>26</sup>still, recommendations for reprise testing in 1 time rather than immediate Colposcopic referral for HPV-positive tests with normal cytology results lead to analogous or only hardly advanced rates of referral to colonoscopy.<sup>27</sup> clinging to recommended webbing intervals is important when using HPV testing for webbing, because repeating the test too soon is more likely to descry flash HPV infections than pre-cancel. This can increase emotional torture and fiscal burden without dwindling cancer prevalence and mortality, so adherence to recommended intervals is important for realizing the benefits of HPV webbing.<sup>28</sup>Of note, some HPV tests may be used alone, whereas others may only be used with concurrent cytology(contesting).

#### Contesting:

Contesting involves taking a cervical cytology sample and an HPV test during the same examination. Samples are collected by a clinician during a spectrum examination. Depending on which tests are used, cytology and HPV tests may be collected independently, or both tests may be performed from a single liquid-

ground cytology sample. Analogous to HPV testing alone, contesting detects lesser than 90 of pre-cancers and cancers with a single screen.<sup>17</sup> periodical negative defenses confer adding protection, with one study of 990,013 women chancing no cervical cancers and many pre-cancers after two negative contests.<sup>22</sup> Webbing with contesting slightly increases the receptivity for detecting high-grade cervical pre-cancers(CIN3 and AIS) and invasive cervical cancers compared with HPV testing alone, detecting roughly five fresh cancers per million women screened.<sup>17,29,30</sup> unusual cytology findings with negative HPV tests may also do in advanced cancers, frequently caused by a cornucopia of necrotic towel in the sample that obscures HPV test results. Still, the utmost advanced cancers are detected because of symptoms and are therefore not preventable via the webbing of asymptomatic populations. A disadvantage of webbing with cytology in addition to HPV testing is the number of unusual results without a substantial reduction in cancer burden. Modeling studies indicate that 640 colonoscopies would be performed per cancer averted when using HPV testing alone, compared with nearly 1000 colonoscopies per averted cancer using contesting. Modeling a population of 100,000 individuals screened over their continuances, contesting would help five fresh cervical cancers and two deaths compared with HPV testing, but with about 50 further false-positive results and colonoscopies.<sup>31</sup>

#### **People's Attitude and Behavior about Vaccination:**

HPV vaccine uptake lags other adolescent vaccines, with 2017 rates at 66 for one cure and 49 for series completion, compared to 89 for Trap and 85 for meningococcal vaccines. Misconceptions, similar to disagreements about its cancer forestalled, safety, necessity, and applicable age, contribute to low uptake. This review refutes five common myths and provides substantiation-based prompts for healthcare professionals to effectively address these enterprises.<sup>32</sup>Cervical cancer is the alternate-deadliest complaint in the world for women after bone cancer. Numerous women who have cervical cancer, when to set up, have formerly entered the final stage, making it delicate to cure. Cervical cancer can avert by using the mortal papilloma vaccine, but numerous women don't vaccinate because they warrant knowledge and information. Grounded on the results of interviews with 20 womanish scholars, 18 didn't know about the mortal papilloma vaccine, and 4 had a history of cervical cancer in their family. This study aimed to determine the relationship between the knowledge and station of womanish scholars towards the mortal papillomavirus vaccine at PelitataHarapan University. This exploration system uses an across-sectional approach with 101 scholars as a sample, and the slice fashion used is intentional slice. The findings of data analysed by Chi square test revealed a p value of 0.002. Finally, there is a relationship between the knowledge and station of womanish scholars toward the mortal papillomavirus vaccine. Further

exploration will probe factors related to stations towards the mortal papillomavirus vaccine other than knowledge.<sup>33</sup>

Around 77.7 of scholars showed some understanding of HPV-related infections, cancer, and vaccination, though knowledge gaps remain. Adding mindfulness is pivotal to promote informed HPV vaccination opinions. Public health juggernauts and the addition of non-age vaccination programs are essential, especially as scholars are generally positive about vaccination. Impulses for healthcare professionals to ameliorate HPV knowledge and communication, along with policy changes to reduce walls, can further support HPV vaccination sweats.<sup>34</sup>In 2017–2018, we surveyed a public sample of 1196 US parents of children 9 to 17 times. We had taped brief films of a prediction providing delivered that addressed 7 HPV vaccine themes that typically elicit queries or ventures. We aimlessly assigned parents to 1 of the communication motifs; Parents also viewed 4 videos on that content in arbitrary order and estimation Parents were more confidence about the HPV vaccine after exposed to dispatches that addressed their lack of understanding about the HPV vaccine, dispatches that included information about cancer forestalled ( $b = 0.11$ ;  $P.001$ ), dispatches that needed an advanced reading position ( $b = 0.02$ ;  $P = .01$ ), and dispatches that were longer ( $b = 0.03$ ;  $P.001$ ). Parents were less confident in HPV vaccine when exposed to dispatches in which urgency was expressed ( $b = -0.06$ ;  $P = .005$ ).<sup>35</sup>

A 2022 single-blind, randomized clinical trial in Shiraz, Iran, studied the impact of an educational intervention based on the Theory of Planned Behavior of knowledge and attitudes toward HPV and its vaccine among women of reproductive age. Eighty-three participants were randomly assigned to intervention and control groups, with data collected through a validated questionnaire. Analysis showed a significant increase in knowledge, attitudes, social norms, perceived behavior control, and willingness to receive the HPV vaccine in the intervention group compared to the control ( $P < 0.05$ ). The study suggests that educational interventions can effectively improve awareness and attitudes toward HPV vaccination in women.<sup>36</sup>This study examined the knowledge, attitudes, and behaviors of teachers in Kahramanmaraş, Turkey regarding HPV and its vaccine. Conducted among 804 teachers from March to June 2015, it revealed that 38.4% of participants had heard of HPV, and 25.7% were aware of the vaccine. Knowledge about HPV was mainly obtained from the internet, and female teachers scored significantly higher in knowledge about HPV and vaccination than male teachers. Overall, teachers showed limited understanding and some misconceptions about HPV and the vaccine, with male teachers displaying a greater knowledge gap than female teachers.<sup>37</sup>

A study conducted from August 15 to October 15, 2022, examined HPV vaccination willingness among 921 female sex workers (FSWs) in Guangxi, China, using the IMB model. Results showed 77.31% were willing to vaccinate, with higher HPV

knowledge, motivation, and behavioral skills significantly increasing willingness ( $P < 0.001$ ). Lower-grade venue FSWs were less willing [OR=0.693,  $P = 0.004$ ], while positive vaccine beliefs [OR=2.144,  $P < 0.001$ ], prior awareness [OR=2.105,  $P < 0.001$ ], perceived benefits [OR=1.134,  $P = 0.002$ ], self-decision-making [OR=1.130,  $P = 0.036$ ], and self-efficacy [OR=1.135,  $P < 0.001$ ] were associated with greater willingness.<sup>38</sup>

### **Importance of Vaccination:**

Vaccination is a safe and effective strategy to help HPV infection and associated cancers. Unborn exploration should concentrate on developing targeted measures to increase HPV vaccination rates among men of all races and ethnicities. Manly teenagers from ethnic and ethnic nonages are more likely to start vaccinations, despite harmonious advice for all groups.<sup>39</sup> The Gardasil quadrivalent, Cervarix bivalent, and Gardasil 9 covalent vaccines aim to help HPV and related conditions. While Gardasil is supposed largely safe, farther unprejudiced, long-term studies are essential to estimate its safety and efficacy, especially since these vaccines are primarily recommended for children.<sup>40</sup> More lately, experimenters have also sought to more understand individual parent and adolescent socio-demographic characteristics that prognosticate vaccine uptake, with expedients of acclimatizing patient care and interventions to ameliorate protection from HPV.<sup>41</sup> Given the HPV vaccines can't help or treat HPV infections, vaccines are recommended primarily for youngish individualizes before implicit exposure to HPV. The vaccines vary in the number of HPV strains that they target. Thus, not all HPV-related malice can be averted through these available vaccines. As vaccine technology advances, new HPV vaccines are likely to be introduced and incorporated into immunization programs that will be suitable to give fresh protection. Especially, remedial HPV vaccines are being developed for head and neck cancer, with clinical trials vulnerable to the vaccines.<sup>42</sup>

### **Male Vaccination:**

HPV infection doesn't simply impact women, it is also associated with genital knobs, mouth, throat, head and neck cancer, congenital cancer, specifically anal and penile cancers in men. As apparent from the data participated by WHO and IARC, numerous countries worldwide have introduced HPV vaccination in males also and have espoused colorful approaches for the same. Pan-gender Vaccination program that extends to adolescent boys was enforced in a number of developed countries, including Australia, Austria, Bermuda, Brazil, Canada, Croatia, England, Germany, Israel, Italy, Lichtenstein, New Zealand, Norway, Serbia, Sweden, and the United States<sup>( 43,44)</sup> as multiple models preliminarily suggested that vaccinating both men and women is more salutary than vaccinating only ladies.<sup>(45-49)</sup> by conceivably dwindling the HPV transmission. Global comparisons suggest that HPV-associated

anal cancers in males are advanced in Asia than in the US. It is also apparent that the mindfulness on HPV and vaccines is relatively among men who have coitus with men (MSM) in Asia. The burden of congenital HPV infections in Asian men ranges astronomically from 1.3(among scholars in Japan) to 89.4(MSM in Thailand), which may be because numerous sexual and gender nonage (SGM) people witness stigmatization by society. It has turned into a fresh hedge for them to seek health-related services, including HPV vaccination.<sup>50</sup>

### **Safety of Vaccination:**

The circumstance of any adverse effect after taking the vaccine in the actors is a specific of the safety of the vaccine. Natural anomalies, significant disability, long-term hospitalization, life-threatening experience, or death are events nominated under severe adverse goods<sup>51</sup>. Antenatal vaccinations are pivotal for both the mama's active impunity against major contagious conditions and the bambino's unresistant impunity against contagious conditions with high morbidity and mortality rates. Live vaccinations are frequently not advised during gestation since they could affect foetalviremia or bacteremia. Utmost inactivated vaccinations are secure<sup>52</sup>. In a study, they summarized the most recent information on HPV vaccinations created at the launch of the twenty-first century. The immunizations have no adverse side effects and are largely safe and effective. In Sweden, both boys and girls were vaccinated as a preventative measure in seminaries. They handed two boluses of the covalent vaccine to this age group. The main thing of the immunization was to lower the prevalence of genital cancer and the lesions that serve as its precursors. The cervix, which is the point of the most significant malice linked to HPV, has primarily been analyzed. Genital knobs are a problematic benign disease that is delicate to treat and constantly has psychosexual impacts.<sup>53</sup> Mainly, HPV vaccination uptake can still be much bettered, and further exploration is needed to understand the causes of ethnical/ ethnic variations in the factors that make vaccination easier. Given that HPV vaccination for men is still fairly new, there is a great chance to advance vaccine developments and public policy, similar to tutoring in seminaries and using social marketing to reach manly teenagers.<sup>54</sup> Also, the maturity (97.1) allowed the HPV vaccine to be safe, with an overall mean score of 8.8 on a scale from 1 to 10 in a study.<sup>55</sup> During the analysis of the vaccine, no party failed.<sup>56</sup>

### **Effects of Vaccination:**

The HPV vaccine was constantly or constantly recommended by the vast maturity(81.5) of GPs who supported girls between the periods of 11 and 12; This get was more likely to happen in those who allowed the vaccine, which was veritably effective in precluding HPV-related conditions in girls between the periods of 12 and 26. Still, allowed the vaccine was largely effective at precluding HPV-related

conditions in boys progressed 12–26 and allowed the safe, they cine was veritably safe, they were more likely to do the same for boys aged 11–12. GPs should be informed about the HPV vaccine to communicate with their patient group and increase content rates regularly. Infections<sup>55</sup> with HPV, cervical cancer, precancerous cervical lesions, and genital knobs have declined in Sweden<sup>53</sup>. The decrease in complaint prevalence within the first 25 times of HPV 4 is thought to be due to the prevention of HPV 6/ 11-related genital issues because cervical malice has a longer natural history.<sup>57</sup> The concern is raised that differences in vaccination completion could increase formerly-being difference in cervical cancer due to black cases' lower completion rates compared to white. The vaccine can be determined for teen population. For the teenage population. The vaccine ensures maximum protection if all the boluses are taken<sup>58</sup>. Regarding the actors' stations, girls aged 12–26 times had a mean score of 9.2 and boys had a mean score of 8.1 for the effectiveness of the HPV vaccine in precluding affiliated conditions. Nearly two-thirds(59.9) and one-third(32.6) of the actors had advanced scores on a 10- point Liker- type<sup>55</sup>. According to studies comparing the mono-, bi-, and quadrivalent preventative HPV vaccines, women who admit the shots between the periods of 24 and 45 had lower situations of neutralizing antibodies. As a result, youthful women aged 15-26 are the most likely to receive vaccinations. Previous research found that Cervarix, a preventive vaccine, provided better protection against HPV infection than Gardasil. Compared to Cervarix, the situations of anti-HPV16 and antiHPV18 antibodies were much lower after using Gardasil. These findings indicate that a supporter cure of the vaccination and the addition of applicable adjuvants can enhance vulnerable responses and raise situations of neutralizing antibodies.<sup>59</sup> A study suggests that delivering the HPV vaccine on a large scale is feasible, with public faith in its safety.<sup>60</sup>

According to an analysis, none of these reviews performed meta-analyses; rather, they qualitatively summarized their findings.<sup>61</sup> This accomplishment is viewed as a steppingstone in lowering the frequency of cancer linked to HPV. The impact of vaccination juggernauts is determined by the content situations attained, perpetration ways (with or without catch-up), and recommendations for vaccine use. Thus, comparing pre- and vaccination HPV frequency is pivotal to assess the vaccine's effectiveness and its effects on our community.<sup>62</sup> In Spain, research shows that 9vHPV immunization has the potential benefits. The 9vHPV vaccination program is more cost effective than the present 4vHPV immunization program, providing major public health benefits.<sup>63</sup>

### **Conclusion:**

This review demonstrated that some forms of HPV can cause cervical cancer. Without precautions, it can easily spread from person to person through sexual contact. Getting an HPV vaccination is one way to prevent this. Vaccination is an

effective and safe procedure. However, the immunization is contraindicated during pregnancy. Further research is expected to address challenges to vaccination adoption in the future years. However, current studies suggest that vaccines have favorable impacts. A new vaccine for preventing cervical cancer in women has been shown to both safe and effective. The conclusions align with the evidence offered. This review helps students learn about preventing cervical cancer with HPV vaccination. This article explains the benefits of these activities and addresses common misconceptions about them.

**Acknowledgment:**

All participants, including staff members, lab technicians, and students of GDCK, BTCST and EWCP are acknowledged by all the authors.

**References:**

- 1) World Health Organization. Human papillomavirus and cancer. Available from: [www.int](http://www.int), 2024.
- 2) Yang DY, Bracken K. Update on the new 9-valent vaccine for human papillomavirus prevention. *Can Fam Physician*. 2016;62(5):399-402.
- 3) World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, May 2017. *Wkly Epidemiol Rec*. 2017;92(19):241-268.
- 4) Canfell K, Kim Jj, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. *Lancet*. 2020;395(10224):591-603.
- 5) Constable C, Ferguson K, Nicholson J, Quinn GP. Clinician communication strategies associated with increased uptake of the human papillomavirus (HPV) vaccine: A systemic review. *CA Cancer J Clin*. 2022;72(6):561-9.
- 6) Epidemiology of HPV infection and HPV-related cancers in Kazakhstan: a review. *AP JCP*. 2018;19(5):1175.
- 7) Soheili M, Keyvani H, Soheili M, Nasser S. Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers. *Med J Islam Repub Iran*. 2021 May 22;35:65.
- 8) Williamson AL. Recent developments in human papillomavirus (HPV) vaccinology. *Viruses*. 2023 Jun 26;15(7):1440.
- 9) De Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country, and HPV type. *Int J Cancer*. 2017;141(4):664–70.
- 10) Cheng L, Wang Y, Du J. Human papillomavirus Vaccines: An Updated Review. *Vaccines*. 2020;8(3):391.

- 11) Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, De Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. *Lancet Glob Health*. 2016;4(7):e453-e463.
- 12) Eun TJ, Perkins RB. Screening for cervical cancer. *Med Clin North Am*. 2020 Nov;104(6):1063-1078.
- 13) Arbyn M, Smith SB, Temin S, et al. Collaboration on self-sampling and HPV testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. *BMJ*. 2018;363:k4823.
- 14) Asciutto KC, Ernston A, Forslund O, et al. Self-sampling and HPV mRNA analyses from vagina and urine compared with cervical samples. *J Clin Virol*. 2018;101:69-73.
- 15) Arrossi S, Thouyaret L, Herrero R, et al. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. *Lancet Glob Health*. 2015;3(2):e85-94.
- 16) Castle PE, Rausa A, Walls T, et al. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. *Prev Med*. 2011;52(6):452-5.
- 17) Schiffman M, Kinney WK, Cheung LC, et al. Relative performance of HPV and cytology components of contesting in cervical screening. *J Natl Cancer Inst*. 2017;
- 18) Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. *J Natl Cancer Inst* 2014;106(8).
- 19) Elfstrom KM, Smelov V, Johansson ALV, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomized controlled trial. *BMJ*. 2014;348:g130.
- 20) Castle PE, Glass AG, Rush RR, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. *J Clin Oncol*. 2012;30(25):3044-50.
- 21) Castle PE, Kinney WK, Xue X, et al. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an observational cohort study. *Ann Intern Med*. 2018;168(1):20-9.
- 22) Smith MA, Canfell K. Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: example from Australia. *Papillomavirus Res*. 2017;3:134-41.
- 23) Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in



- the United States: a 24-year population-based study. *GynecolOncol* . 2000;78(2):97-105.
- 24)Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. *Cancer Epidemiol Biomarkers Prev*. 2005;14(9):219-9.
- 25)Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized controlled trial. *Lancet Oncol*. 2010;11(3):249-57.
- 26)Egemen D, Cheung LC, Chen X, et al. Risk estimates supporting the 2019 ASCCP Risk Based Management Consensus Guidelines. *J Low Genit Tract Dis*. 2020;24(2):132-43.
- 27)US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018;320(7):674-86.
- 28)Arbyn M, Sasieni P, Meijer CJLM, et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. *Vaccine*. 2006;24Suppl 3.S3/78-89.
- 29)Austin RM, Onisko A, Zhao C. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV contesting. *Am J ClinPathol*. 2018;150(5):385-92.
- 30)Kim JJ, Burger EA, Regan C, et al. Screening for cervical cancer in primary care: a decision analysis for the U.S. Preventive services task force. Agency for Health-care Research and Quality (US). 2018. Available at: [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)
- 31)Bednarczyk RA. Addressing HPV vaccine myths: practical information for healthcare providers. *Human vaccines & immunotherapeutics*. 2019;15(7-8):1628-38.
- 32)Seo JKC, Neri H, Maturan AM, Cathryne J, Debby C. The relationship between knowledge with attitudes of college students towards the HPV vaccine. *JurnalKeperawatan Priority*. 2024;7(2):26–39.
- 33)Cheema S, Abraham A, Maisonneuve P, Jithesh A, Chaabna K, al Janahi R, et al. HPV infection and vaccination: a cross-sectional study of knowledge, perception, and attitude to vaccine uptake among university students in Qatar. *BMC Public Health*. 2024;24:2316.
- 34)Shah PD, Calo WA, Gilkey MB, Boynton MH, Dailey SA, Todd KG, Robichaud MO, Margolis MA, Brewer NT. Questions and concerns about HPV vaccine: A communication experiment. *Pediatrics*. 2019;143(2):e20181872.
- 35)Rafeie L, Vizeshfar F, Nick N. The effect of education based on planned behavior theory on women's knowledge and attitudes about human papillomavirus. *Sci Rep*. 2024;14:18581.

- 36) Keten HS, Ucer H, Dalgaci AF, Isik O, Ercan Ö, Guvenc N. Knowledge, attitude, and behavior of teachers regarding HPV (Human Papillomavirus) and vaccination. *J Cancer Educ.* 2021;36(3):584-590.
- 37) He ZY, Wei JH, Jiang JM, Hu R, Qi GZ. Analysis of influencing factors of HPV vaccination willingness of female sex workers in urban entertainment venues based on the IMB model in Guangxi, China. *BMC Womens Health.* 2024;24(141).
- 38) Landis K, Bednarczyk RA, Gaydos LM: Correlates of HPV vaccine initiation and provider recommendation among male adolescents, 2014 NIS-Teen. *Vaccine.* 2018, 36:3498-504.
- 39) Soliman M, Oredein O, Dass CR. Update on safety and efficacy of HPV vaccines: focus on Gardasil. *Int J Mol Cell Med.* 2021 Sep 1;10(2):101-13.
- 40) Landis K, Bednarczyk RA, Gaydos L. Correlates of HPV vaccine initiation and provider recommendation among male adolescents, 2014 NIS-Teen. *Vaccine.* 2018 Jun 7;36(24):3498-3504.
- 41) Shapiro, G.K. HPV Vaccination: An Underused Strategy for the Prevention of Cancer. *Curr Oncol.* 2022, 29, 3780-3792.
- 42) L. Cheng, Y. Wang, J. Du. Human papillomavirus vaccines: an updated review. *Vaccines (Basel).* 2020;8(3):391.
- 43) Prue G, Baker P, Graham D, et al. It is time for universal HPV vaccination. *Lancet.* 2018;392(10151):913-4.
- 44) Bogaards JA, Wallinga J, Brakenhoff RH, et al. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: Bayesian evidence synthesis. *BMJ.* 2015;350:h2016.
- 45) Elfström KM, Lazzarato F, Franceschi S, et al. Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. *J Infect Dis.* 2016;213(2):199-205.
- 46) Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. *Vaccine.* 2011;29(46):8443-8450.
- 47) Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. *N Engl J Med.* 2008;359(8):821-32.
- 48) Datta S, Pink J, Medley GF, et al. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK. *BMC Infect Dis.* 2019;19(1):552.
- 49) Khallouf H, Grabowska AK, Riemer AB. Therapeutic vaccine strategies against human papillomavirus. *Vaccines (Basel).* 2014;2(2):422-62.
- 50) Soliman M, Oredein O, Dass CR. Update on safety and efficacy of HPV vaccines: focus on Gardasil. *Int J Mol Cell Med.* 2021;10:101-13.
- 51) Arora M, Lakshmi R. Vaccines - safety in pregnancy. *Best Pract Res Clin Obstet Gynaecol.* 2021;76:23-40.

- 52) Wikström A, Elfgrén K. HPV vaccines effective and safe. *Lakartidningen*. 2021;118:2106.
- 53) Landis K, Bednarczyk RA, Gaydos LM. Correlates of HPV vaccine initiation and provider recommendation among male adolescents, 2014 NIS-Teen. *Vaccine*. 2018;36(26):3498-504.
- 54) HPV Vaccination Attitudes and Behaviors among General Practitioners in Italy [Internet]. 2022 [cited 2022 Aug 2]. Available from: [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)
- 55) Olsson SE, Restrepo JA, Reina JC, et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. *Papillomavirus Res*. 2020;10:100203.
- 56) Ortiz AP, Ortiz-Ortiz KJ, Ríos M, Marrero E, Pérez CM, Suárez E. Modelling the effects of quadrivalent human papillomavirus (HPV) vaccination in Puerto Rico. *PLoS One*. 2017;12(9):e0184540.
- 57) Widdice LE, Bernstein DI, Leonard AC, Marsolo KA, Kahn JA. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. *Pediatrics*. 2011;127(1):77-84.
- 58) Yousefi Z, Aria H, Ghaedrahmati F, et al. An update on human papilloma virus vaccines: history, types, protection, and efficacy. *Front Immunol*. 2021;12:805695.
- 59) Mandal R, Banerjee D, Gupta K, Chatterjee P, Vernekar M, Ray C. Experience of human papillomavirus vaccination project in a community set up-an Indian study. *Asian Pac J Cancer Prev*. 2021;22:699-704.
- 60) Villa A, Patton LL, Giuliano AR, et al. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: umbrella review of systematic reviews. *J Am Dent Assoc*. 2020;151(4):245-54.e24.
- 61) Purriños-Hermida MJ, Santiago-Pérez MI, Treviño M, et al. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain. *PLoS One*. 2018;13:e0201653.
- 62) De La Fuente J, Hernandez Aguado JJ, San Martín M, Ramirez Boix P, Cedillo Gómez S, López N. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain. *Hum Vaccin Immunother*. 2019;15:1949-61.